Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 14/20 | 0.53 |
| ▸ | BACE2 | Q9Y5Z0 | 8/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15956968 | 1.00 | BACE1 (0.53) | BACE1BACE2LMNAGRM5CYP2C9 | |
| SCHEMBL15366624 | 0.88 | BACE1 (0.54) | BACE1BACE2LMNAGRM5 | |
| SCHEMBL14716596 | 0.81 | BACE1 (0.61) | BACE1BACE2LMNAGRM5 | |
| SCHEMBL19725813 | 0.76 | BACE1 (0.63) | BACE1BACE2LMNAGRM5CYP2C9 | |
| SCHEMBL15839801 | 0.76 | BACE1 (0.53) | BACE1BACE2 | |
| SCHEMBL15768794 | 0.74 | BACE1 (0.38) | BACE1BACE2 | |
| SCHEMBL15799730 | 0.74 | BACE1 (0.41) | BACE1BACE2LMNA | |
| SCHEMBL15769264 | 0.74 | BACE1 (0.41) | BACE1BACE2LMNA | |
| SCHEMBL19725795 | 0.73 | BACE1 (0.59) | BACE1BACE2LMNA | |
| SCHEMBL19725797 | 0.73 | BACE1 (0.48) | BACE1BACE2LMNACYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2956458-B1 | HETEROARYL-SUBSTITUTED HEXAHYDROPYRANO[3,4-D][1,3]THIAZIN-2-AMINE COMPOUNDS | PFIZER (US) | 2017-08-09 | — | — | EP | disclosed |
| EP-2956458-B1 | HETEROARYL-SUBSTITUTED HEXAHYDROPYRANO[3,4-D][1,3]THIAZIN-2-AMINE COMPOUNDS | PFIZER (US) | 2017-08-09 | — | — | EP | disclosed |
| US-9192612-B2 | Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds | PFIZER INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-9192612-B2 | Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds | PFIZER INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20150224110-A1 | Heteroaryl-Substituted Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | PFIZER INC. (US) | 2015-08-13 | — | — | US | disclosed |
| US-20150224110-A1 | Heteroaryl-Substituted Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | PFIZER INC. (US) | 2015-08-13 | — | — | US | disclosed |
| US-20150224110-A1 | Heteroaryl-Substituted Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | PFIZER INC. (US) | 2015-08-13 | — | — | US | disclosed |
| US-9045499-B2 | Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds | PFIZER INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-9045499-B2 | Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds | PFIZER INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-9045499-B2 | Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds | PFIZER INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-20140364426-A1 | Heteroaryl-Substituted Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | PFIZER (US) | 2014-12-11 | — | — | US | disclosed |
| US-20140364426-A1 | Heteroaryl-Substituted Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | PFIZER (US) | 2014-12-11 | — | — | US | disclosed |
| US-20140364426-A1 | Heteroaryl-Substituted Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | PFIZER (US) | 2014-12-11 | — | — | US | disclosed |
| US-8865706-B2 | Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds | PFIZER INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-8865706-B2 | Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds | PFIZER INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-8865706-B2 | Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds | PFIZER INC. (US) | 2014-10-21 | — | — | US | disclosed |
| WO-2014125394-A1 | HETEROARYL-SUBSTITUTED HEXAHYDROPYRANO [3,4-d][1,3] THIAZIN-2-AMINE COMPOUNDS | PFIZER INC. (US) | 2014-08-21 | — | — | WO | disclosed |
| US-20140228356-A1 | Heteroaryl-Substituted Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | PFIZER INC. (US) | 2014-08-14 | — | — | US | disclosed |
| US-20140228356-A1 | Heteroaryl-Substituted Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | PFIZER INC. (US) | 2014-08-14 | — | — | US | disclosed |
| US-20140228356-A1 | Heteroaryl-Substituted Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | PFIZER INC. (US) | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228356-A1 | Heteroaryl-Substituted Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | TBXA2R, UGT1A3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | BACE1 927/4885BACE2 636/4885LMNA 2828/4885 |
| US-20150224110-A1 | Heteroaryl-Substituted Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | TBXA2R, UGT1A3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | BACE1 927/4885BACE2 636/4885LMNA 2828/4885 |
| US-20140364426-A1 | Heteroaryl-Substituted Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | TBXA2R, UGT1A3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | BACE1 927/4885BACE2 636/4885LMNA 2828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.